Saxenda in Michigan (2026)
liraglutide · GLP-1 weight management · Michigan
About Saxenda
FDA-approved daily injectable liraglutide for chronic weight management. Older-generation GLP-1, daily dosing.
See the full Saxenda review for dosing, efficacy data, side effects, and the full pharmacy + telehealth program comparison.
Insurance coverage for Saxenda in Michigan
Since January 1, 2026, Michigan Medicaid covers GLP-1s for obesity only for morbid obesity, after documented failure of other weight-loss interventions including PDL-preferred anti-obesity drugs, and only to avoid bariatric surgery. Prior authorizations approved before the change stay valid until their 6-month term ends.
| Carrier | Saxenda status | Detail |
|---|---|---|
| Aetna | Covered (prior auth required) | Saxenda is FDA-approved for chronic weight management. We have not found a public Aetna coverage document for Saxenda, so confirm coverage, prior authorization and tier on your plan's drug list or by calling the number on your insurance card. |
| Blue Cross Blue Shield | Limited coverage | Blue Cross Blue Shield of Michigan named Saxenda among the weight-loss GLP-1s it stopped covering for fully insured large groups from January 1, 2025, and Blue Cross Blue Shield of Massachusetts ended GLP-1 coverage for weight loss from January 1, 2026. Other Blue plans set their own rules. |
| UnitedHealthcare | Covered (prior auth required) | Saxenda is part of the same optional UnitedHealthcare weight-loss program as Wegovy and Zepbound, with no step through another drug in the policy. It has a shorter first approval (4 months) and a lower renewal bar (4% weight loss). |
| Cigna | Covered (prior auth required) | Under Cigna policy IP0621, brand Saxenda is approved only after trying generic liraglutide, unless an inactive-ingredient difference would cause a serious reaction. The first approval lasts 4 months and renewal requires at least 4% weight loss. |
| Humana | Not covered | Medicare Part D does not cover Saxenda for weight loss, and Saxenda is not one of the drugs in the Medicare GLP-1 Bridge. This applies to Humana Medicare drug plans. |
| Kaiser Permanente | Limited coverage | Saxenda is FDA-approved for chronic weight management. We have not found a public Kaiser Permanente coverage document for Saxenda, so confirm coverage, prior authorization and tier on your plan's drug list or by calling the number on your insurance card. |
| Anthem | Limited coverage | Saxenda is FDA-approved for chronic weight management. We have not found a public Anthem commercial coverage document for Saxenda, so confirm coverage, prior authorization and tier on your plan's drug list or by calling the number on your insurance card. |
| Medicare | Not covered | Part D excludes Saxenda for weight loss, and Saxenda is not one of the drugs in the Medicare GLP-1 Bridge (Wegovy, Zepbound KwikPen and Foundayo are). |
| Medicaid | Varies by plan | California Medi-Cal removed Saxenda from its drug list for weight loss on January 1, 2026, and MassHealth ended coverage of Saxenda for weight loss on July 3, 2026. Other states set their own rules. |
| TRICARE | Covered (prior auth required) | TRICARE lists Saxenda among covered weight-loss medications for Prime, Select and the premium-based plans, with prior authorization and a network prescriber. TRICARE For Life and direct-care-only beneficiaries are excluded since August 31, 2025. |
| GEHA | Covered (prior auth required) | GEHA covers Saxenda with prior authorization in 2026: non-preferred on the High, Standard, HDHP and Elevate Plus plans, preferred on Elevate. Generic liraglutide is also covered with prior authorization on all GEHA plans. |
Telehealth and prescribing in Michigan
A telehealth clinician must be licensed in Michigan to prescribe Saxenda to you while you are in Michigan.
Michigan's IMLC membership lapsed on March 28, 2025 and was restored by Public Act 6 of 2026 (HB 5455), signed March 26, 2026.
- Source: Michigan Legislature: HB 5455
Platforms differ in which drugs they prescribe, insurance handling, and clinical model. See our platform comparisons.
Compounded liraglutide
On April 30, 2026, FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list, which would stop outsourcing facilities from compounding them from bulk ingredients. The comment period was extended to July 30, 2026. As of September 15, 2026, no final decision has been published. The proposal does not address 503A compounding for an individual patient's documented clinical need.
Saxenda in Michigan: common questions
Is Saxenda legal in Michigan?+
Yes. Saxenda (liraglutide) is FDA-approved and legal in all 50 US states including Michigan. State-level differences appear in Medicaid coverage and clinician licensing, not in the legality of the medication itself.
Can I get Saxenda via telehealth in Michigan?+
Yes, from a clinician licensed in Michigan. A telehealth clinician must be licensed in Michigan to prescribe Saxenda to you while you are in Michigan. Michigan's IMLC membership lapsed on March 28, 2025 and was restored by Public Act 6 of 2026 (HB 5455), signed March 26, 2026.
Does Michigan Medicaid cover Saxenda?+
Limited coverage for weight loss. Since January 1, 2026, Michigan Medicaid covers GLP-1s for obesity only for morbid obesity, after documented failure of other weight-loss interventions including PDL-preferred anti-obesity drugs, and only to avoid bariatric surgery. Prior authorizations approved before the change stay valid until their 6-month term ends.
What's the cheapest way to get Saxenda in Michigan?+
The main paths are insurance with prior authorization if your plan covers it, manufacturer cash-pay programs, or telehealth programs that include the medication. NovoCare Pharmacy sells Wegovy pens to cash-pay patients for $349 a month ($199 a month for the first two months for new patients through December 31, 2026). LillyDirect sells Zepbound vials for $299 (2.5 mg), $399 (5 mg), and $449 (7.5 to 15 mg) a month when refilled on time.
Is compounded Saxenda still available in Michigan?+
Compounding rules are federal, not set by Michigan. On April 30, 2026, FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list, which would stop outsourcing facilities from compounding them from bulk ingredients. The comment period was extended to July 30, 2026. As of September 15, 2026, no final decision has been published. The proposal does not address 503A compounding for an individual patient's documented clinical need.